SHR-A2102 + HRS-4642

**SHR-A2102 + HRS-4642** is a combination therapy under clinical investigation for the treatment of advanced solid tumors, particularly those harboring difficult-to-target mutations. SHR-A2102 is a nectin-4–directed antibody-drug conjugate (ADC) developed by Jiangsu Hengrui Medicine. It targets nectin-4, a cell surface adhesion protein overexpressed in various solid tumors, delivering a cytotoxic payload directly to cancer cells, thereby reducing systemic toxicity. HRS-4642 is a highly selective, non-covalent, high-affinity inhibitor of KRAS G12D, one of the most common oncogenic KRAS mutations found in solid tumors, especially pancreatic, colorectal, and lung cancers. HRS-4642 has shown robust in vitro and in vivo anti-tumor activity against KRAS G12D–mutant cancers. The combination aims to leverage both targeted cytotoxicity (via nectin-4 targeting) and genetic driver inhibition (via KRAS G12D blockade) to address treatment-resistant cancers. The combination is currently being evaluated in early-phase trials for efficacy and safety in patients with advanced, unresectable, or metastatic solid tumors[1][3][9].

Brand names

SHR-A2102 + HRS-4642

Other names

SHR-A2102 plus HRS-4642SHR-A-2102 plus HRS-4642SHR-A 2102 plus HRS-4642